Market Overview:
The global hemophilia gene therapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of hemophilia, technological advancements in gene therapy, and rising investments by key players in this field. Hemophilia A is the most common type of hemophilia and accounts for approximately 80% of all cases. Hemophilia B is the second most common type and accounts for approximately 20% of all cases. North America dominates the global hemophilia gene therapy market, followed by Europe. The high prevalence of hemophilia in these regions drives the demand for novel therapies such as gene therapies.
Product Definition:
Hemophilia gene therapy is a treatment that uses genes to fix or replace unhealthy or missing genes. This therapy can be used to treat diseases caused by a lack of certain proteins, including hemophilia.
Hemophilia A:
Hemophilia A is a rare genetic disorder caused by the lack of coagulation factor in the body. It’s primary symptom is bleeding into any part of the body, especially during exercise or injury. The other symptoms include easy bruising, nosebleed, frequent infections (more than average), and low platelet count leading to easy bleeding and pain when injured.
Hemophilia B:
Hemophilia B is a rare genetic disorder that affects the blood clotting mechanism. It is estimated that 1 in 5,000 babies are born with this condition every year. The disease mostly occurs among males and females carrying a defective gene for coagulation factor (F9).
The market size was valued at USD 2.8 billion in 2018 and is expected to register a CAGR of XX% over the forecast period.
Application Insights:
Based on application, the global market is segmented into hemophilia A gene therapy, hemophilia B gene therapy and other applications. The other applications include disorders of blood coagulation such as Christmas disease and Bleeding Disorder of uncertain significance (BSDOS). Hemophilia A held the largest share in terms of revenue in 2017 owing to availability of approved products for all three indications globally. Moreover, there are ongoing clinical trials for new drug development for various indications including hemophilia which is expected to propel growth over the forecast period.
Hemophilia B followed behind due to presence of only two approved products-Ferring Pharmaceuticals' Alprolix and Pfizer's Travenolone injection which were launched relatively late compared to their counterparts namely Ferring Pharmaceuticals' Feraheme and Janssen Sciences Ireland Ltd.'s Epzicom1/Ceravase1 respectively that were launched earlier.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a substantial number of players, availability of advanced technologies and high awareness levels amongst people about this therapy. Moreover, approval and commercialization of products in this region are easier as compared to other regions due to higher healthcare infrastructure & development.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare facilities & infrastructure along with growing target population base in emerging countries such as China & India. Furthermore, increasing investments by governments for developing novel therapies will drive regional market growth during the forecast period.
Growth Factors:
- Increasing incidence of hemophilia
- Growing demand for gene therapy products
- Rising awareness about hemophilia gene therapy treatments
- Technological advancements in hemophilia gene therapy treatments
- Availability of government funding for research and development of new hemophilia gene therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemophilia Gene Therapy Market Research Report
By Type
Hemophilia A, Hemophilia B, Hemophilia Gene Therap
By Application
Hemophilia A Gene Therapy, Hemophilia B Gene Therapy
By Companies
Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, Hemophilia Gene Therap
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Hemophilia Gene Therapy Market Report Segments:
The global Hemophilia Gene Therapy market is segmented on the basis of:
Types
Hemophilia A, Hemophilia B, Hemophilia Gene Therap
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hemophilia A Gene Therapy, Hemophilia B Gene Therapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Spark Therapeutics
- Ultragenyx
- Shire PLC
- Sangamo Therapeutics
- Bioverativ
- BioMarin
- uniQure
- Freeline Therapeutics
- Hemophilia Gene Therap
Highlights of The Hemophilia Gene Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hemophilia A
- Hemophilia B
- Hemophilia Gene Therap
- By Application:
- Hemophilia A Gene Therapy
- Hemophilia B Gene Therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemophilia Gene Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemophilia is a rare blood disorder that affects the ability of the blood to clot. Hemophilia A, which is the most common form of hemophilia, results when there is a deficiency or absence of one type of protein in the blood. Hemophilia B results from a deficiency or absence of another protein in the blood. Hemophilia C occurs when there is a combination of two different types of proteins that are needed for normal clotting.nnThere are currently three approved gene therapies for hemophiliacs: Factor VIII replacement therapy (FVIII), FIXation therapy (FIX), and rFVIIa treatment (rFIX). FVIII replacement therapy uses recombinant DNA technology to create an artificial version of factor VIII called humanized prokaryotic expression vector-derived factor VIII concentrate, or hPIVCu00ae . FIXation therapy uses recombinant DNA technology to create an artificial version as well as antibodies against FIX which bind and neutralize FIX activity inside cells so that they cannot cause bleeding episodes. rFIX treatment replaces defective fusions between chromosome 9 and chromosome 17 in people with hemophilia B, leading to improved bleeding control by promoting formation new clots outside affected cells instead
Some of the key players operating in the hemophilia gene therapy market are Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, Hemophilia Gene Therap.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemophilia Gene Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hemophilia Gene Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hemophilia Gene Therapy Market - Supply Chain
4.5. Global Hemophilia Gene Therapy Market Forecast
4.5.1. Hemophilia Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hemophilia Gene Therapy Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hemophilia Gene Therapy Market Absolute $ Opportunity
5. Global Hemophilia Gene Therapy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Type
5.3.1. Hemophilia A
5.3.2. Hemophilia B
5.3.3. Hemophilia Gene Therap
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hemophilia Gene Therapy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Application
6.3.1. Hemophilia A Gene Therapy
6.3.2. Hemophilia B Gene Therapy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hemophilia Gene Therapy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hemophilia Gene Therapy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hemophilia Gene Therapy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hemophilia Gene Therapy Demand Share Forecast, 2019-2026
9. North America Hemophilia Gene Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hemophilia Gene Therapy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hemophilia Gene Therapy Market Size and Volume Forecast by Application
9.4.1. Hemophilia A Gene Therapy
9.4.2. Hemophilia B Gene Therapy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hemophilia Gene Therapy Market Size and Volume Forecast by Type
9.7.1. Hemophilia A
9.7.2. Hemophilia B
9.7.3. Hemophilia Gene Therap
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hemophilia Gene Therapy Demand Share Forecast, 2019-2026
10. Latin America Hemophilia Gene Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hemophilia Gene Therapy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hemophilia Gene Therapy Market Size and Volume Forecast by Application
10.4.1. Hemophilia A Gene Therapy
10.4.2. Hemophilia B Gene Therapy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hemophilia Gene Therapy Market Size and Volume Forecast by Type
10.7.1. Hemophilia A
10.7.2. Hemophilia B
10.7.3. Hemophilia Gene Therap
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hemophilia Gene Therapy Demand Share Forecast, 2019-2026
11. Europe Hemophilia Gene Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hemophilia Gene Therapy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hemophilia Gene Therapy Market Size and Volume Forecast by Application
11.4.1. Hemophilia A Gene Therapy
11.4.2. Hemophilia B Gene Therapy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hemophilia Gene Therapy Market Size and Volume Forecast by Type
11.7.1. Hemophilia A
11.7.2. Hemophilia B
11.7.3. Hemophilia Gene Therap
11.8. Basis Point Share (BPS) Analysis by Type
1.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hemophilia Gene Therapy Demand Share, 2019-2026
12. Asia Pacific Hemophilia Gene Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hemophilia Gene Therapy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hemophilia Gene Therapy Market Size and Volume Forecast by Application
12.4.1. Hemophilia A Gene Therapy
12.4.2. Hemophilia B Gene Therapy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hemophilia Gene Therapy Market Size and Volume Forecast by Type
12.7.1. Hemophilia A
12.7.2. Hemophilia B
12.7.3. Hemophilia Gene Therap
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hemophilia Gene Therapy Demand Share, 2019-2026
13. Middle East & Africa Hemophilia Gene Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hemophilia Gene Therapy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hemophilia Gene Therapy Market Size and Volume Forecast by Application
13.4.1. Hemophilia A Gene Therapy
13.4.2. Hemophilia B Gene Therapy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hemophilia Gene Therapy Market Size and Volume Forecast by Type
13.7.1. Hemophilia A
13.7.2. Hemophilia B
13.7.3. Hemophilia Gene Therap
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hemophilia Gene Therapy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hemophilia Gene Therapy Market: Market Share Analysis
14.2. Hemophilia Gene Therapy Distributors and Customers
14.3. Hemophilia Gene Therapy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Spark Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Ultragenyx
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shire PLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sangamo Therapeutics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bioverativ
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioMarin
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. uniQure
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Freeline Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Hemophilia Gene Therap
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook